The startup Senseledge, based in Rome, has introduced a revolutionary AI technology that significantly cuts down the time needed to diagnose lung, thyroid, and pancreatic cancers.
Traditionally, histological exams could take anywhere from 5 to 21 days to yield results.
However, this new AI-based system delivers reliable digital images in just two to three minutes.
This innovation, known as Convergence, is a result of collaboration with the Campus Biomedico in Rome and is supported by nearly one million euros from the PNRR funds aimed at enhancing biomedical research.
Senseledge, which won a Ministry of Health grant, is currently certifying this technology as a medical device, with plans to market it within a year and a half.
The technology is particularly useful during surgical procedures for immediate diagnosis.
Unlike traditional methods, the new system does not require extensive processing of the biological sample, using only a reagent called acridine to produce high-quality digital images swiftly.
Senseledge, which also operates in Calabria, collaborates with Anna Crescenzi from the University of La Sapienza and provides software solutions to public healthcare facilities across Italy.
Additionally, Senseledge has developed Revelio, an AI system for breast cancer diagnosis that organizes mammographic studies by malignancy and lesion presence, aiding oncologists in reducing false negatives.
According to recent reports, there were 395, 000 new cancer cases last year, with breast cancer being the most diagnosed, followed by colorectal, lung, prostate, and bladder cancers.
Unfortunately, there has been a 3% national decline in screening participation.